Jantzen Matli
Family Medicine · McAlester, OKNPI 1205337201
Payments from drug & device makers
Across 113 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$574
- Novo Nordisk$450
- Pfizer$172
- Lilly USA, LLC$154
- Astellas Pharma US Inc$107
- AstraZeneca$100
- plus $472 from 16 others
What the payments were for
- Food & beverage$2,027100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $574 |
| Novo Nordisk | 32 | $450 |
| Pfizer | 12 | $172 |
| Lilly USA, LLC | 10 | $154 |
| Astellas Pharma US Inc | 4 | $107 |
| AstraZeneca | 6 | $100 |
| Sanofi-aventis U.S. LLC | 5 | $84 |
| Merck | 4 | $63 |
| Intuitive Surgical | 1 | $50 |
| Novartis | 3 | $46 |
| Dexcom, Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| GSK | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
How this compares
$2,027 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 83 | $91,231 |
| OzempicSemaglutide | 71 | $67,809 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $51,896 |
| JardianceEmpagliflozin | 81 | $51,524 |
| EliquisApixaban | 91 | $48,015 |
| RybelsusSemaglutide | 28 | $39,121 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $13,826 |
| MyrbetriqMirabegron | 42 | $12,755 |
| TradjentaLinagliptin | 19 | $11,068 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $9,269 |
| GemtesaVibegron | 15 | $9,136 |
| Duloxetine Hcl | 137 | $6,290 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,353 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $4,447 |
| Atorvastatin Calcium | 259 | $3,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $450 | $106,93099 claims |
| Lilly USA, LLCMounjaro | $154 | $91,23183 claims |
| Boehringer IngelheimJardiance, Tradjenta | $18 | $62,592100 claims |
| GSKTrelegy Ellipta | $18 | $51,89664 claims |
| PfizerEliquis | $172 | $48,01591 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $100 | $19,17838 claims |
| Astellas Pharma US IncMyrbetriq | $107 | $12,75542 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $22 | $9,13615 claims |
| AbbVieSynthroid | $574 | $1,27722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in McAlester
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.